Insight Molecular Diagnostics Inc. has appointed Donnie Purto as Senior Vice President of Sales to lead commercialization efforts for its transplant diagnostic product, GraftAssureDx, which is currently under FDA review. Purto brings over 20 years of sales leadership experience in diagnostics and healthcare, including a decade at Natera. This move prepares iMDx for the anticipated market launch of GraftAssureDx, a test that measures donor-derived cell-free DNA to monitor transplant rejection. The company aims to disrupt the transplant diagnostics market with this innovative product pending regulatory approval in 2027.
Insight Molecular Diagnostics' new sales leader appointment provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 14, 2026 19:01 WIB: Out of 150 priced health-sector US stocks, 105 rose and 40 fell. Notable movers include LQDA at USD 37.65 with a 40.43% increase, ARWR at USD 61.98 up 6.62% with a typical hold time of 5 days, and ENVB at USD 1.34 down 4.29% with a typical hold time of 14 days.
BlackRock reported a strong third quarter with adjusted earnings of $15.93 per share, beating estimates by a wide margin and marking a 38% increase year-over-year. Revenue grew 19% to $7.75 billion, driven by $205 billion in net client inflows, inclu...
Home BancShares will release its Q3 2026 earnings report on October 14, with analysts expecting earnings per share of $0.64 and revenue around $293-$294 million, marking a 5.5% revenue increase and 4.9% EPS growth from last year. The bank's P/E ratio...
Hyperion Materials & Technologies has acquired The Ultra-Met Company, a tungsten carbide manufacturer based in Urbana, Ohio, to expand its capabilities in serving the US aerospace and defense sectors. Ultra-Met works closely with the US Department of...
Morgan Stanley reported Q3 earnings per share of $3.03, surpassing analyst estimates of $2.93 and $2.83 consensus. Revenue reached $20.34 billion, a 12% increase year-over-year and above the $19.93 billion estimate. Strong equity trading and record w...
Bank of New York Mellon is set to report its Q3 2026 earnings, with analysts expecting earnings per share of $2.27 and revenue of $5.55 billion. This represents an 18.3% increase in earnings and a 9.5% rise in revenue compared to the previous year, d...
